Possible role of matriptase in the diagnosis of ovarian cancer.
There are increasing data that suggest a role for the serine protease matriptase and its inhibitor, hepatocyte growth factor activator inhibitor-1, in the pathogenesis and progression of ovarian cancer. This review will discuss the matriptase/inhibitor system in the context of ovarian cancer and examine the possibility that this system might be a useful therapeutic and/or diagnostic target in this disease.
Johnson
Michael D
MD
Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA. johnsom@georgetown.edu
Oberst
Michael D
MD
Lin
Chen-Yong
CY
Dickson
Robert B
RB
D014408:Biomarkers, Tumor; D018450:Disease Progression; D004789:Enzyme Activation; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000145:classification / Q000175:diagnosis* / Q000628:therapy; D012697:Serine Endopeptidases / Q000032:analysis / Q000502:physiology*; D015842:Serine Proteinase Inhibitors / Q000032:analysis / Q000502:physiology; D014357:Trypsin / Q000032:analysis / Q000502:physiology*
D014408:Biomarkers, Tumor; D015842:Serine Proteinase Inhibitors; D012697:Serine Endopeptidases; C485595:matriptase; C485596:ST14 protein, human; D014357:Trypsin